• metastatic/advanced mGC or mGEJC
• mGC or mGEJC - 1st line (L1)
• mGC or mGEJC - L1 - all population
• mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2
• mGC or mGEJC - L1 - HER2 negative 1
• mGC or mGEJC - L1 - HER2 positive
• mGC or mGEJC - L1 - PDL1 positive 4
• mGC or mGEJC - 2nd Line (L2)
• mGC or mGEJC - L2 - all population 4
• mGC or mGEJC - L2 - PDL1 positive 1
• mGC or mGEJC - maintenance (M)
• mGC or mGEJC - M - HER2 negative 1
• mGC or mGEJC - M - HER2 neg/PDL1 positive 1
• gene alteration defined cancer

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab alone

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs paclitaxel

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  mGC or mGEJC - L2 - PDL1 positive;